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Rat sarcoma (RAS) familymembers are small GTPases that control a number of signaling pathways important
for normal cellular proliferation. Therefore, it is no surprise that a significant portion of human tumors express
constitutively active mutated RAS proteins, which leads to deregulation of RAS signaling pathways, resulting
in pathological perturbations of cell growth and death. Although the molecular details of RAS signaling
cascades are well understood, there is still a largely unmet need for small molecule probes to control RAS
signaling in space and time. More broadly, given the prevalence of mutated RAS in cancer, the need to
translate the insights obtained from using small molecule probes into clinically useful drugs is also sig-
nificant. In this review, we introduce RAS proteins and the signaling pathways they are involved in, and
discuss some of the innovative chemical biology approaches to regulate RAS signaling, which include the
exploitation of newly identified binding pockets, covalent inhibitors for mutated RAS, and RAS localization
impairment.Rat sarcoma (RAS) small GTPases are encoded by ras genes,
which are among the most prominent oncogenes identified in
cancer.Mutations in RAS proteins can be found in approximately
20%–30% of all human tumors (Prior et al., 2012), which caught
the interest of academic and pharmaceutical research from the
time they were identified. Despite their potential as drug targets,
no anti-RAS therapies are clinically available because inhibition
of RAS was found to be exceptionally challenging. This review
summarizes the efforts made and the failures and successes
faced in interfering with RAS signaling in space and time. First,
we give an overview of signaling pathways involving RAS and
their role in pathology. Second, the posttranslational lipid modi-
fications of RAS and RAS membrane association and distribu-
tion in space and time are discussed. Third, we elaborate on
the use of small molecules for the modulation of RAS signaling,
including direct targeting of RAS and interference with RAS
distribution.
RAS Proteins
RAS proteins are membrane-bound molecular switches that
cycle between an inactive GDP bound form and the active
GTP bound state. Upon stimulation by upstream signals, gua-
nine nucleotide exchange factors (GEFs), such as RAS guanyl-
releasing protein (RASGRP) and Son of Sevenless 1 and 2
(SOS1 and 2) stimulate the exchange of GDP for GTP on RAS
and thereby switch the GTPase ‘‘on.’’ RAS signaling most
notably promotes cell survival, but also influences adhesion,
apoptosis and migration, and other cellular programs. GTPase
activating proteins (GAPs), including Neurofibromin 1 (NF1)
and p120, conversely trigger GTP hydrolysis and thus terminate
signaling (Figure 1; Pylayeva-Gupta et al., 2011).
The three ras genes encode four different RAS proteins
(H-RAS, N-RAS, and the splice variants K-RAS4b and the less
abundant 4a), which all have a highly conserved G domain butChemistry & Biology 2differ in their hypervariable C-terminal region (HVR). The HVR is
posttranslationally modified with lipid groups for membrane
anchorage.
Signaling via RAS Proteins
RAS proteins are key components of several divergent signaling
cascades,most notably the RAF/MEK/ERK andPI3K/PDK1/AKT
pathways (Figure 2). These cascades are initiated by a variety of
upstream signals. Binding of growth factors to their cognate re-
ceptors, such as the epidermal growth-factor receptor (EGFR),
the fibroblast growth-factor receptor, or the platelet-derived
growth-factor receptor, trigger a cascade of events, including
recruitment of the adaptor protein GRB2 (growth factor recep-
tor-bound protein 2) to the receptor, followed by binding of
SOS to GRB2 and subsequent nucleotide exchange and RAS
activation by SOS. In addition, G protein-coupled receptors
and nonreceptor proteins can recruit GRB2 after activation, and
additional GEFs have been identified (Downward, 2003).
Signaling downstream of RAS branches in several pathways,
most prominently the kinase signaling cascades RAF/MEK/
ERK and PI3K/PDPK1/AKT (reviewed in Berndt et al., 2011; Saini
et al., 2013; Eser et al., 2014).
In the RAF/MEK/ERK pathway, RAS activates one of the ho-
mologous ARAF, BRAF, and CRAF1 kinases (rapidly accelerated
fibrosarcoma). RAF phosphorylates the mitogen-activated pro-
tein kinases 1 and 2 (MEK1 and MEK2) which, in turn, phosphor-
ylate and activate the mitogen-activated protein kinases (MAPK)
extracellular signal-regulated kinases (ERK1/2), resulting in the
activation of a group of effector proteins, including the members
of the transcription factor family of ETS proteins, such as ELK1.
Activated phosphoinositide 3-kinases (PI3Ks) modify phos-
phatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol
(3,4,5)-trisphosphate (PIP3), which recruits the AKT complex,
followed by the activation of target of rapamycin (mTOR), which1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1185
Figure 1. Schematic Representation of the RAS Activation Cycle
Inactive GDP-bound RAS is activated via signals from extracellular stimuli by
means of GEFs, like SOS1 and 2, which induce GTP binding and stimulate
downstream signaling. GAPs, including NF1 and p120, subsequently induce
GTP hydrolysis and thereby terminate RAS signaling.
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proteins. Phosphorylated PI3K also activates RAC via RAC-
selective GEFs, which influences cytoskeleton reorganization
(Heid et al., 2011).
Cross-signaling between and feedback loops within the RAS
cascades introduces additional degrees of cell fate regulation.
A positive feedback loop between the RAF/MEK/ERK and
PI3K/PDPK1/AKT cascades includes phosphorylation of RAF
by AKT (Zimmermann and Moelling, 1999), and in a negative
feedback loop, TORC1 inhibition induces AKT and ERK (Chan-
darlapaty, 2012). Notably, the paradoxical induction of cancer
upon treatment with first-generation BRAF kinase inhibitors
was explained by the ability of these compounds to activate
the RAF-MEK-ERK pathway in a RAS-dependent manner de-
pending on their cellular context (Hatzivassiliou et al., 2010).
Moreover, BRAF(V600E) inhibition activates EGFR, thus sustain-
ing the proliferation of colon cancer cells. BRAF inhibitors are
effective in melanoma cell lines, however, because they express
less EGFR (Prahallad et al., 2012). A similar counterintuitive
reactivation of RAS signaling was observed using other RAF in-
hibitors. MEK and RAF were found to be connected in a negative
feedback loop, because the MEK mixed lineage kinases (MLK1-
4) stimulate the MEK/ERK pathway upon RAF inhibition (Maru-
siak et al., 2014). MEK also negatively regulates RAS signaling
by activating ERK, which phosphorylates SOS (Buday et al.,
1995; Dong Chen et al., 1996; Porfiri and McCormick, 1996).
Phosphorylation of SOS reduces its guanine exchange factor
ability and thus reduces RAS signaling (Anderson et al., 2011).
An additional ERK feedback mechanism involves ERK phos-
phorylation of RAF, which reduces RAS interaction. The loss of
this negative feedback mechanism is the basis for the ineffec-
tiveness of MEK inhibitors (Lito et al., 2013).
In very recent studies, the interplay between wild-type and
mutant Ras genes was investigated. Wild-type RAS was found
to antagonize mutant RAS signaling, because its depletion re-
sulted in an upregulation of ERK phosphorylation in cells and in
tumor models. K-RAS, however, was not inhibited by the other
isoforms of RAS and vice versa. The specificities of this negative
feedback mechanism are not fully understood yet, but possible
explanations could involve competition between the RAS iso-
forms for effectors, regulators, and localization, or the existence
of another inhibitory pathway (Bentley et al., 2013; Young et al.,1186 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Lt2013). Conversely, siRNAs targeting oncogenic KRAS in a
pancreatic cancer cell line led to upregulation of wild-type
KRAS signaling. This phenomenon could denote a negative
feedback mechanism of oncogenic KRAS, whereby wild-type
KRAS is desensitized (Young et al., 2013). The exact regulatory
mechanisms of the interplay between wild-type and mutant
RAS are clearly not elucidated yet.
RAS Pathways and Their Connection to Pathology
Because the RAS signaling pathway is linked to cell survival,
overactivation results in various pathological outcomes, most
notably in cellular transformation. Activating point mutations in
the ras genes are common in various tissue types. Mutation rates
are particularly high in biliary tract cancer, where 25%of the RAS
proteins are altered and pancreatic cancer with almost 60%
mutated KRAS. KRAS mutations can also be found in 17% of
the cases of lung cancer and in 31% of the cancer incidences
in peritoneum (COSMIC database, 2014). These frequencies
concern tissue types. The mutation rate in tumor types can
even be higher. The eight cases of pancreatic carcinosarcoma
in the COSMIC database all contain a KRAS point mutation.
For autoimmune pancreatitis, 90% was KRAS mutated. In
contrast, pancreatic islet cells are mutated in only 3% of the in-
cidences. KRAS is the most frequently mutated oncogene
(86%), NRAS overactivation occurs in 11% of the ras gene mu-
tations and HRAS accounts for 3% of the cases (Forbes et al.,
2011; Table 1). Oncogenic RAS point mutations aremostly found
on Gly-12, Gly-13, and Gln-61 in the G-domain and impair the
interaction with GAPs such that GTP bound to RAS is not hydro-
lyzed and RAS is constantly ‘‘on.’’
Carcinogenic signaling can also be caused by malfunction of
other components of the RAS pathways. Upstream of RAS, the
overexpression of growth factor receptors can induce amplifica-
tion of the RAS signaling pathway. For instance, overexpression
of human epidermal growth factor receptor 2 (HER2) is associ-
ated with more than 30% of breast cancer cases (Mendelsohn
and Baselga, 2000; Mitri et al., 2012).
Proteins that are directly associated with RAS can also stimu-
late carcinogenesis. Deletion of tumor suppressive GAPs, such
as neurofibromin, is associated with hyperactive RAS (Weiss
et al., 1999) and neurofibromin (NF1) deficiency combined with
a KRAS mutation induces more severe acute myeloid leukemia,
than individual malfunction (Cutts et al., 2009).
Finally, activating mutations in RAS effector proteins down-
stream of the oncogene can result in signaling increase and
consequently tumor growth. Thus, mutations in the BRAF gene
increase cell proliferation (Davies et al., 2002), and mutated
ERK is connected to melanoma development (Smalley, 2003).
In the PI3K/PDPK1/AKT pathway, mutation of the tumor sup-
pressor PTEN results in sporadic cancers because the protein
can no longer dephosphorylate the second messenger phos-
phatidylinositol (3,4,5)-triphosphate (Simpson and Parsons,
2001). Other malfunctions include PI3K mutations and activation
of mTOR or AKT (Ocana et al., 2014).
Lipidation and Distribution of RAS Proteins
Lipid Modifications of RAS Proteins
All RAS proteins are lipidated at C-terminal cysteine residues
to ensure transport and localization to membranes for properd All rights reserved
Figure 2. Simplified Overview of Selected
Signaling Pathways Emerging from RAS
Proteins
RAS activates, among others, the RAF/MEK/ERK
and the PI3K/PDPK1/AKT pathway. RAS activates
RAF, which phosphorylates MEK1/2. Subse-
quently, MEK1/2 phosphorylates and activates the
MAPK kinases ERK1/2, which results in the acti-
vation of a group of effector proteins, including
ETS proteins, such as ELK1. Furthermore, RAS-
GTP activates PI3Ks, which recruit the AKT com-
plex, through PDK1, followed by the activation of
mTOR. Phosphorylated PI3K also activates Rac,
which influences cytoskeleton reorganization.
Crosstalk between the pathways takes place at
AKT, which stimulates RAS and mTOR that
downregulates ERK1/2.
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H-RAS, N-RAS and K-RAS4A are additionally S-palmitoylated
in their HVR. Farnesylation is not reversible, whereas the palmitic
acid thioesters are subject to hydrolysis by thioesterases.
The RAS proteins embody a C-terminal CAAX motif (C is a
cysteine residue, A is an aliphatic amino acid, and X is methio-
nine or serine) which is recognized by farnesyl transferase (FT)
to attach the C15 farnesyl group to the cysteine residue. In
case of FT-inhibition or depletion, geranylgeranylation may
replace farnesylation (Holstein and Hohl, 2012).
Subsequent C-terminal truncation by the endoprotease RAS
converting enzyme 1 (RCE1) and methylation of the resulting
C-terminal cysteine carboxylic acid by isoprenyl-cysteine-car-
boxymethyltransferase (ICMT) to increase hydrophobicity com-
plete posttranslational processing (Hrycyna et al., 1991).
Impaired RCE1 activity leads to localization defects and per-
turbed RAS signaling (Boyartchuk et al., 1997; Otto et al.,
1999). In ICMT/ cells, GFP-tagged K-RAS is cytosolic and
signaling is impaired (Bergo et al., 2000).
In addition to farnesylation,H-,N-RAS,andK-RAS4AareS-pal-
mitoylated close to the prenylated cysteine group (K-RAS4A will
not be discussed further as it is not very abundant). The extra
lipidation ensures a higher membrane affinity and aids in the
correct localization of RAS proteins. S-palmitoylation occurs on
the Golgi by ZDHHC9 (zinc finger DHHC domain-containing
protein 9) and GCP16. After palmitoylation, the fully modified
proteins are transported to the plasma membrane via vesicular
transport (Swarthout et al., 2005).
In contrast to farnesylation, palmitoylation is reversible and
after RAS depalmitoylation by acylprotein thioesterases 1 andChemistry & Biology 21, September 18, 2014 ª2, the protein is solubilized and subse-
quently released from the plasma mem-
brane (Rusch et al., 2011). Retrapping of
the depalmitoylated Ras-proteins at the
Golgi and palmitoylation close the cycle.
This shuttling cycle determines H/N-Ras
localization and allows for an additional
level of regulation in RAS signaling.
Membrane Association and
Distribution in Space and Time
The spatial organization of RAS proteins
is important in the regulation of theirsignaling activities. The small GTPases are localized at different
subcellular sites, depending on their posttranslational modif-
ications. The proteins are biosynthesized in the ribosomes on
the endoplasmic reticulum (ER). Subsequently, posttranslational
farnesylation occurs in the ER membrane. In addition, H- and
N-RAS are palmitoylated at the Golgi apparatus. Finally, the
RAS proteins cycle between the plasma membrane, where
they execute their most important signaling function, and endo-
membranes. The RAS proteins are asymmetrically distributed
over the cellular membranes and at steady state, KRAS is
strongly enriched at the plasma membrane, whereas HRAS
localizes to the plasma membrane and the Golgi and NRAS is
predominantly found at the Golgi (Rocks et al., 2006). This sug-
gests that the localization is maintained by active transport,
because energy-independent transport would result in RAS dis-
tribution over all available membranes via spontaneous intracel-
lular membrane exchange. The active transport of H-, N-, and
KRAS follows a common principle but differs in the individual
components involved for the differently lipidated RAS isoforms.
Lipidation in general increases membrane affinity of all RAS
isoforms. N- and H-RAS carry two and three-lipid residues,
respectively. KRAS is only farnesylated, but it is additionally
equipped with a stretch of six basic, and therefore protonatable,
lysine residues to strengthen the interaction with the negatively
charged inner leaflet of the plasma membrane.
For farnesylated KRAS plasmamembrane enrichment ismain-
tained through active transport by the farnesyl-binding shuttling
protein PDEd (phosphodiesterase of retinal rod subunit d;
Figure 4). This guanine nucleotide disscociation inhibitor-like
solubilizing factor acts as chaperone protein that binds and2014 Elsevier Ltd All rights reserved 1187
Table 1. Prevalence of RAS Point Mutations in Different Tissues
with Incidences Higher than 5%
Tissue KRAS (%) HRAS (%) NRAS (%)
Biliary tract 25 – –
Cervix 7 8 –
Endometrium 16 – –
Gastrointestinal tract 5 – –
Genital tract 5 – –
Hematopoietic/lymphoid 5 – 10
Large intestine 35 – –
Lung 17 – –
Meninges – – 6
Nervous system – – 15
Ovary 12 – –
Pancreas 59 – –
Penis – 7 –
Peritoneum 31 – –
Prostate 5 – –
Salivary gland – 9 –
Skin – 10 15
Small intestine 20 – –
Stomach 6 – –
Thyroid – – 6
Upper aerodigestive tract – 8 –
Urinary tract 5 9 –
For significant data all cancer types are combined per tissue (COSMIC
database, 2014). –, not applicable.
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small G proteins. Depletion of PDEd results in RAS mislocaliza-
tion and consequently in attenuated signaling (Chandra et al.,
2012). Spatiotemporal cycling of KRAS was investigated by
means of fluorescence imaging and computational cellular au-
tomaton 3D-reaction-diffusion simulations. KRAS has a plasma
membrane residence time of 7.4 min and is released via spon-
taneous dissociation (enhanced by phosphorylation of a serine
close to the polybasic lysine stretch) or endocytic vesiculation,
which is five times faster than plasma membrane dissociation.
The outer leaflet of the endosomal KRAS-carrying membranes
loses its negative charge upon internalization and membrane
fusion, which results in an increase in dissociation rate of
KRAS, because the additional electrostatic interactions be-
tween the polybasic stretch of KRAS and the membrane are
weakened. The dissociation creates a soluble KRAS fraction,
which is bound and shuttled in the cell by PDEd. Finally,
KRAS is released from PDEd to the perinuclear compartment
by the small GTPase ARL2, which forms a transient heterotri-
meric complex with the KRAS-PDEd complex. KRAS is trapped
by the negatively charged recycling endosomes and trans-
ported to the plasma membrane, where it again participates in
signal transduction until the next round in cycling (Schmick
et al., 2014; Ismail et al., 2011). In addition to PDEd, the lectins
Galectin-1 and -3 have also been suggested to bind farnesy-
lated H-RAS and K-RAS, respectively (Paz et al., 2001;
Elad-Sfadia et al., 2004), but their possible involvement in1188 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier LtRAS-shuttling has not been shown and definite proof for direct
interaction between RAS and Galectin in vitro is lacking.
HRAS- and NRAS-localization is regulated by an analogous
transportation cycle characterized by the same basic elements:
release from the plasma membrane (by endocytosis or by spon-
taneous dissociation after depalmitoylation), binding and shut-
tling by PDEd in the cytosol, trapping at a subcellular site (by
repalmitoylation at the Golgi apparatus), and retrograde vesicu-
lar transport to the plasma membrane (Figure 5). However, due
to the different lipid modifications the details differ. For these
multilipidated proteins, reversible S-palmitoylation regulates
membrane attachment and dictates the subcellular location of
RAS. Palmitoylation of H- and NRAS occurs predominantly at
the Golgi apparatus, after which the proteins are transferred to
the plasma membrane via the secretory pathway by vesicular
transport. Depalmitoylation, which leads to membrane release
and solubilization of RAS, occurs abundantly in the cell and
depalmitoylated RAS is redirected back to the Golgi by PDEd-
mediated transport. In the Golgi membrane, the proteins are
reacylated and then transported to the PM and the cycle is
repeated (Rocks et al., 2010). The process of both de- and repal-
mitoylation occurs with a half-life in the second range and allows
rapid trapping of the proteins at the Golgi. During its 24 hr life-
time, HRAS is estimated to undergo 70 cycles before it is
degraded (Magee et al., 1987). Because HRAS embodies two
palmitic acid thioesters, its depalmitoylation at and release
from the plasma membrane take longer than that for NRAS,
which carries only one thioester. Therefore, NRAS is released
and retrapped faster and is predominantly localized in steady
state at the Golgi, whereas HRAS is enriched at the plasma
membrane. Thus, the kinetics of de- and repalmitoylation and
transport by PDEd and the secretory pathway determine the
spatiotemporal localization of H- and N-RAS.
Because correct localization is required for proper RAS
signaling and the KRAS- and the H/NRAS-cycles are decisive
for subcellular localization of the RAS isoforms, mislocalization
of RAS proteins by interfering with these cycles emerged as a
novel approach to small molecule modulation of RAS signaling.
Small Molecule Modulation of RAS Signaling
Due to the strong connection of RAS to cancer development, the
proteins have been of major interest to the pharmaceutical in-
dustry and academia for decades, because small inhibitory mol-
ecules of RAS signaling could be novel anticancer drugs. Several
strategies have been explored to inhibit RAS signaling, but
despite these widespread efforts, clinically anti-RAS therapies
have not become available yet. Direct targeting of RAS proved
unsuccessful because no obvious tractable cavities could be
identified with previous crystal structures except their nucleotide
binding sites, and therefore, protein-protein interactions that
mediate RAS signaling are difficult to target (Wang et al., 2012)
Posttranslational modification inhibitors also did not render any
clinically viable results. Although farnesyl transferase inhibitors
were very promising in cellular and animal studies, in clinical tri-
als they did not affect tumor growth, mostly because RAS was
lipidated by geranylgeranyltransferase after blocking farnesyl-
transferase (Berndt et al., 2011). The RAS protein family, how-
ever, still remains an attractive drug target because of its crucial
role in cancer and current research has focused on thed All rights reserved
Figure 3. The HRV of the Different Isoforms
of RAS, which Define the PlasmaMembrane
Targeting Region
All proteins are farnesylated and methylated on
the C terminus. HRAS, KRAS4A, and NRAS are
additionally palmitoylated. KRAS contains a poly-
basic lysine stretch that mediates the interaction
between the negatively charged inner leaflet of the
plasma membrane.
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sively understand the different pathways and to find novel
ways for interference.
Chemical Biology Tools in RAS Research
A major contribution of chemical biology research to RAS
signaling investigations stems from the development of semisyn-
thetic methods to obtain fully modified RAS proteins and other
GTPases in quantities that enable structural crystallographic
studies, cell biology research, and small inhibitory molecule
screening (Brunsveld et al., 2006).
The introduction of posttranslational modifications, such as
farnesylation and palmitoylation in the case of RAS, is typical
for eukaryotes and can therefore not be achieved by standard
protein expression in Escherichia coli. The proteins, therefore,
need to be expressed in eukaryotic expression systems, which
strongly increase costs, time, and efforts, while decreasing the
yields. In addition, expression of homogeneously palmitoylated
RAS proteins proved not to be efficient. Protein-ligationmethods
not only offer the opportunity to generate chemically modified
proteins to introduce either natural functional groups, but also
give access to unnatural groups such as fluorescent, metal-
chelating, or bio-orthogonal structures.
Three different synthetic or enzymatic methods were devel-
oped for the introduction of lipids onto RAS proteins. First, pre-
nyltransferases were used in vitro for the attachment of farnesyl
and geranylgeranyl groups onto the CAAX motif cysteine of full-
length E. coli-expressed RAS (McGeady et al., 1995) and RAB
(Thoma¨ et al., 2000). Further processing enzymes ensure the
cleavage of the terminal three amino acids and C-terminal
methylation (Figure 6A). This method, however, gives limited
access to proteins with unnatural functional groups (Kale et al.,
2003; Kalinin et al., 2001). In a second approach, the lipid group
is chemically introduced onto a peptide representing the C-ter-Chemistry & Biology 21, September 18, 2014 ªminal residues of the RAS protein and
this lipo-peptide is incorporated via a
maleimidocaproyl ligation (Figure 6B).
Thismethod requires a protein with C-ter-
minal cysteine and a lipo-peptide with
an N-terminal maleimide and yields a
nonnatural thioether bond and a free car-
boxylic acid at the connection site (Bader
et al., 2000; Kuhn et al., 2001). In the final
method, a lipo-peptide representing the
C-terminal amino acids is modified with
a protected cysteine and incorporated
via native chemical ligation (Figure 6C;
Chong et al., 1997). This reaction yields
not only a native chemical bond, butalso a free thiol at the connection site (Chen et al., 2010). The
availability of (near-) native RAS proteins strongly forwarded
the biological elucidation of their role in signal transduction and
anti-RAS drug discovery.
Small Molecule Interference with RAS Localization
Mislocalization of RAS results in impaired signal transduction
and affects tumor growth. Several strategies were explored to
interfere with the spatiotemporal distribution of RAS for both
fundamental chemical biology research and ultimately applica-
tion to drug discovery. The most extensively studied strategy in-
volves lipidation impairment, because nonlipidated RAS proteins
are not directed to the plasmamembrane. Initially, impairment of
posttranslational modification by means of farnesyl transferase
inhibition was explored. Two decades of research led to the
development of a variety of CAAX peptidomimetic structures,
such as tipifarnib, lonafarnib, and BMS-214662, which potently
and selectively inhibit farnesyl transferase (Figure 7A; Berndt
et al., 2011; Holstein and Hohl, 2012). The small molecules
showed promising inhibition of HRAS farnesylation in cells,
leading to impaired downstream RAF/MEK/ERK signaling and
inhibited tumor growth in animals. Additionally, cell cycle pro-
gression, angiogenesis, and apoptosis were affected. However,
the effects in cultured cells could not be translated into clinically
efficacious drugs. Under the conditions of farnesyl transferase
inhibition, RAS proteins can be geranylgeranylated and directed
to the plasmamembrane, leading tominimal effects of the drugs.
More than 70 phase I, II, and even III clinical trials have been con-
ducted for both solid tumors and hematological malignancies
but all led to the conclusion that the tumors could circumvent
the loss of farnesyltransferases (Berndt et al., 2011). Geranylger-
anyltransferase inhibitors, too, showed promising results in
cellular context but phase I clinical trials were stopped to inves-
tigate the safety of the drug (GGTI-2417 and GGTI-2418;2014 Elsevier Ltd All rights reserved 1189
Figure 4. Schematic Representation of KRAS Distribution in Space
KRAS is farnesylated in the ER and transported to the recycling endosomes by
PDEd, where its release is aided by ARL. Subsequently, the ensodomes fuse
with the plasma membrane. Release from the membrane occurs either via
spontaneous release or via endocytosis. The pool of free KRAS is again
transported to the recycling endosomes by PDEd.
Figure 5. Schematic Representation of H- and N-RAS–Depicted by
One RAS Protein—Distribution in Space
RAS is farnesylated in the ER and transported by PDEd to the Golgi, where it is
palmitoylated. RAS travels to the plasma membrane via vesicular transport,
where it is depalmitoylated. The protein is spontaneously released from the
membrane and is transported to the Golgi by PDEd.
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nylation inhibitor (L-778123) also did not display clinical efficacy
because in vivo experiments showed that the intended target
KRASwas not affected (Figure 7C; Lobell et al., 2002). Combina-
tion drug therapy with FTIs and chemotherapeutic agents such
as cisplatin showed higher responses, but still did not yield the
anticipated response (Adjei et al., 2001). Notably, farnesyl trans-
ferase inhibitors also halted tumor growth expressing wild-type
RAS, leading to the conclusion that they exert their mode of
action by inhibiting the farnesylation of a different protein. A
series of other farnesylated proteins could be responsible for
the antitumor activity, such as farnesylated CENPE, PRL1, and
RND3 among others; however, a clear target has not been iden-
tified to date (Berndt et al., 2011).
Other strategies to influence the localization of RAS involve the
inhibition of the depalmitoylating thioesterases APT-1 and APT-2
with the covalent, b-lactone inhibitors Palmostatin B and M
(Figure 7D). This strategy is counterintuitive because at first
sight, inhibition of depalmitoylation should increase membrane
attachment and thereby signaling of H- and N-RAS. However,
inhibition of the de/repalmitoylation cycle in general, that is,
also at the stage of depalmitoylation, leads to impaired
localization and thereby signaling of H- and N-RAS. The perma-
nently palmitoylated proteins remain membrane-bound and are1190 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltdistributed over all cellular membranes via spontaneous mem-
brane exchange and internalization and can therefore not be
retrapped at theGolgi fromwhere they shuttle to their subcellular
destination.
This strategy draws from principles of systems biology
because it targets the RAS-localization system in general, rather
than focusing on particular enzymes, which according to con-
ventional arguing would have to be the RAS-palmitoyl transfer-
ases. Thus, in this thinking, impairment of the RAS cycle is the
goal, and the precise point of intervention is of secondary
concern. APT-1/2 inhibition eventually led to repartitioning of
palmitoylated N- and H-Ras to endomembranes and subse-
quent downregulation of RAS signaling in MDCK cells with acti-
vating mutation in the H-RAS isoform (Dekker et al., 2010).
Boronic and borinic acid based derivatives were also identified
as potent and nontoxic APT inhibitors after an elaborate library
screen (Figure 7E). The small molecules showed strong inhibition
of ERK phosphosylation in vivo and additionally exhibited a
very low off rate, which is beneficial for long-term phenotypic
effect (Zimmermann, T.J. et al., 2013). In addition, piperazine de-
rivatives were identified in a competitive activity-based profiling
approach that selectively inhibited APT1 and 2 inmice (Figure 7F;
Adibekian et al., 2012). Furthermore, the known tyrosine phos-
phatase inhibitor phenylarsine oxide and the thiol-crosslinker
dibromobimane were found to block the palmitoylation of
HRAS (Figure 7G). The two palmitoylatable cysteines in the
HVR of this RAS isoform were covalently bound by these small
molecules, making them unavailable for palmitoylation, which
consequently resulted in altered H-RAS membrane partition in
cells (Oeste et al., 2011). It remains to be seen, however, how
these thiol-reactive compounds behave in animal models
because off-target effects are to be expected.
By analogy to the systems biology-based approach of inter-
fering with the de/repalmitoylation cycle for H/N-RAS, the cycled All rights reserved
Figure 6. Chemical and Enyzymatic Methods to Obtain Lipidated Proteins
(A) Enzymatic approach.
(B) MIC ligation.
(C) Native chemical ligation.
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was targeted. To this end, small inhibitory molecules were devel-
oped to specifically block the interaction between KRAS4B and
the solubilizing factor PDEd. Because PDEd is essential for the
correct localization of KRAS and incorrect distribution reduces
KRAS signaling, which should result in hampered tumor growth,
it was hypothesized that inhibition of their interactions could yield
the same result. For inhibitor identification, an ALPHA screen
was set up using His-tagged PDEd and a biotinylated 11-mer
farnesylated peptide representing the KRAS C terminus, and
a library of ca. 150,000 compounds was tested for inhibitors
(Zimmermann, G. et al., 2013; Zimmermann et al., 2014). In the
screen, several benzimidazole-based inhibitory compounds
were identified that were subsequently analyzed with biophysi-
cal techniques and X-ray crystallography. Surprisingly, the hy-
drophobic binding pocket of PDEdwas simultaneously occupied
by two benzimidazole compounds. Synthetic coupling of these
two hit structures and subsequent optimization yielded the
high-affinity PDEd inhibitor deltarasin (Kd = 38 ± 16 nM;
Figure 7H). Fluorescence microscopy studies confirmed the hy-
pothesis that disruption of the PDEd/KRAS interaction relocal-
ized KRAS to endomembranes and additionally impaired ERK
phosphorylation in human pancreatic duct adenocarcinoma
cells. Moreover, deltarasin inhibited tumor growth in human
pancreatic carcinoma mouse model xenografts. The inhibition
of the PDEd/KRAS interaction proves the power of a systems
biology approach to target KRAS signaling.
Finally,anumberof farnesyl-derivedcompoundsweredesigned
to inhibit the prenyl-binding interactions between RAS and
farnesyl-bindingproteins thatcould interferewithRAS localization.
S-farnesylthiosalicylic acid (salirasib; Figure 7I) was proposed to
targetgalectins incells and to inhibit the interactionofRASproteins
withmembrane-bound receptors. The compounds failed in phase
II clinical trials due to low efficacy (Paz et al., 2001; Elad-Sfadia
et al., 2004; Bustinza-Linares et al., 2010). Furthermore, the farne-
sylated dibenzodiazepioneTLN-4601 (Figure 7J) induced reducedChemistry & Biology 2Ras-GTP levels and increased apoptosis of human pancreatic
epithelial cells, but failed in phase II clinical trials for patients with
glioblastoma (Campbell et al., 2010; Mason et al., 2012).
Furthermore, fendiline, which was originally discovered as an
L-type voltage-gated Ca2+ channel inhibitor, was identified in a
screen searching for small molecule inhibitors of K-RAS mem-
brane interactions (Figure 7K). Due to the observed membrane
dissociation of RAS, the downstream signaling in BHK cells
was impaired (van der Hoeven et al., 2013).
Direct Targeting of RAS with Small Molecules
Most of the current research for interference with RAS signaling
includes targeting the pathway upstream and most importantly
downstream of RAS. However, direct targeting of RAS proved
to be extremely challenging (Saini et al., 2013, Spiegel et al.,
2014). Initial RAS signaling inhibition was logically sought in
competition with GTP analogs (Noonan et al., 1991), because
the RAS signaling pathway is switched on after binding GTP.
However, because GDP and GTP are abundantly available at
millimolar concentrations in the cell and the affinity of RAS for
the nucleotides lies in the picomolar range, the development of
competing GTP analogs was not successful.
Because RAS has a very low intrinsic nucleotide exchange
rate, the exchange of GDP for GTP is aided by GEFs. Blocking
their function was, therefore, suggested to impair RAS signaling
because RAS/GTP is only formed in small amounts. The protein-
protein interaction interface of RAS and its GEF SOS is shallow
and interference therefore is difficult. However, hydrogen-bond
surrogate-constrained peptides derived from SOS antagonized
RAS binding with micromolar affinity (Kd = 28–158 mM) and
impaired RAS signaling in cultured cells. It is interesting to note
that the unconstrained peptide did not influence RAS/SOS bind-
ing (Patgiri et al., 2011). The stabilization itself may also prevent
proteolysis of the peptide, but the affinity may be too low for in-
depth characterization. Furthermore, two separate research
groups identified a transient ligand-binding pocket on RAS in1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1191
Figure 7. Structures of Inhibitors that
Interfere with RAS Signaling
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low millimolar inhibitors also interfered with SOS binding and
attenuated RAS signaling in HEK cells (Figure 8A; Maurer et al.,
2012; Sun et al., 2012). Molecular dynamics simulations indicate
that andrographolide and its benzylidene derivatives (Figure 8B;
Jada et al., 2008) bind directly to the switch regions of wild-type
RAS and the K-RasG12V mutant, blocking the GDP-GTP ex-
change and impairing RAS signaling (Hocker et al., 2013).
Furthermore, Ras$GTP binding small molecules identified
in silico showed Ras-effector interaction impairment in vivo.
The current compounds have low affinities, however, and chem-
ical modifications should increase their potency to make the
compounds suitable for further studies (Shima et al. 2013).
Mutant KRAS with G12C point mutations occurs frequently in
lung cancer but it is a relatively rare mutation in other cancer
types. As opposed to the glycine in wild-type KRAS, the cysteine
SH-group is reactive and therefore, in principle amenable to1192 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltd All rights reservedchemical modification. Exploitation of
this difference in reactivity may allow
discrimination between the different
forms of KRAS. Two research groups
independently identified compounds
that irreversibly bind to cysteine-12.
Crystallographic studies indicated that
electrophilic inhibitors (Figure 8C) bind
beneath the effector binding switch II re-
gion of the mutated protein, thus disrupt-
ing the interactions with downstreamRAF
and perturb the native nucleotide prefer-
ence to favor GDP over GTP (Ostrem
et al., 2013). Additionally, covalent modi-
fication with the GDP analog, SML-8-
73-1, as confirmed with crystallographic
studies (Hunter et al., 2014) and a prodrug
derivative, SML-10-70-1 (Figure 8D),
locked themutant RAS in the GDP-bound
state, which decreased the level of phos-
phorylated ERK and AKT in H358 cells
(Lim et al., 2014).
Conclusions and Outlook
Mutations inRASGTPases contribute sig-
nificantly to the development of various
types of cancer and the proteins therefore
quickly caught the attention of the aca-
demic and pharmaceutical community
for their potential as drug targets. The
RAS signaling pathway is endogenously
involved in cell survival, apoptosis, adhe-
sion, and migration. Activating mutations
in RAS are major contributors to cancer.
Despite the possibility of RAS modulation
for therapeutic intervention, all explored
anti-RAS therapies failed in clinical trials.Theprotein familywas therefore long regardedas ‘‘undruggable,’’
but the development of innovative approaches to targeting RAS
signaling as a method of antitumor therapy renewed the interest
in this very important drug target. The strategies are aimed at pre-
vention of RAS-GEF interactions to circumvent GTP binding,
direct targeting of RAS, the inhibition of RAS-effector interactions
to block signal transduction, and a systems biology approach to
impair RAS signaling by perturbing its localization.
RAS-SOS binding is the most intensively investigated RAS-
GEF interaction to prevent GDP/GTP exchange to avert sig-
naling. Several low micromolar inhibitors were identified based
on constrainedpeptides and indole, sulfonamide, andphenol de-
rivatives (Patgiri et al., 2011;Maurer et al., 2012; Sun et al., 2012).
Chemical alteration of these basic structures should now ensure
higher affinities for biological efficacy. It remains aquestion, how-
ever, if prevention of GEF interactions will truly influence the RAS
signaling pathway in vivo because mutated RAS, which causes
Figure 8. Structures of Inhibitors Targeting RAS
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Reviewsignaling overactivation, is often arrested in theGTP-bound state
and might not depend on the interaction with GEFs (Wang et al.,
2012). Therefore, these inhibitors mostly target wild-type RAS,
which might not have the desired outcome. A different strategy
to avoid RAS activation is the covalent inhibition of mutated
RAS proteins. This method offers a new way of interfering with
the signaling pathway and is expected to suffer less from toxicity,
because such inhibitors do not target wild-type RAS (Lim et al.,
2014;Ostremet al., 2013).However, the specificity of these inhib-
itors in vivo needs to be determined because a specific binding of
cysteines in other proteins is likely.
Targeting downstream effectors in the RAS signaling cascade
did not always result in downregulation of cancerous signaling
but uncovered complex networks of feedback loops and cross-
talk within the divergent RAS signaling cascades. For instance,
BRAF kinase inhibition in melanoma cell lines caused a decrease
in signaling, but an elevation of EGFR response in colon cancer
cells (Prahallad et al., 2012). The therapeutic value of these inhib-
itors is ambiguous; they do, however, offer powerful chemical
biology tools for further elucidation of the RAS signaling pathway,
which is still not fully understood. Crosstalk between the RAS
signaling cascades increases downstream signaling and predict-
ing the therapeutic outcomewhile targeting these proteins is very
difficult. However, investigation of downstream proteins as drug
targets is interesting because different signaling pathways areChemistry & Biology 2triggered in different tumor types. Targeting a combination of
RAS signaling players may be a promising therapeutic interven-
tion. Furthermore, the interplay between wild-type and mutated
RAS isstill under investigation.Wild-typeRASshowsantagonistic
effects on its mutated counterpart; therefore, its inhibition could
increase RAS signaling. On the other hand, wild-type RAS was
also shown to be desensitized for growth factors by mutated
RAS. Therefore, inhibition would increase the response to EGF
signaling (Bentley et al., 2013; Young et al., 2013). These interac-
tions exemplify the complex nature of RAS signaling and prove
that additional investigations of the RAS cascades are justified.
Incorrect lipidation patterns result in deviated localization and
impair RAS signaling and consequently reduced tumor growth.
Therefore, a systems biology-based approach was investigated
aimed at impairing the lipidation cycle of H- and N-RAS. In this
case, the distribution of RAS proteins as a whole is targeted to
interfere with the signaling cascades. APT1 and -2 inhibitors
caused permanent palmitoylation of H- and N-RAS and hence
dislocated the proteins and reduced RAS signaling (Dekker
et al., 2010; Adibekian et al., 2012; Zimmermann, T.J. et al.,
2013). The specificity and efficacy of these inhibitors need to
be investigated in vivo to judge the therapeutic efficiency. In anal-
ogy to the systems biology approach of interfering with H-and
N RAS localization, the interaction between KRAS and its solubi-
lizing factor PDEd was targeted. The inhibitor deltarasin was
identified through a library screen to perturb the KRAS/PDEd
interaction and indeed impaired KRAS localization and signaling
in cells and in human pancreatic carcinoma mouse model xeno-
grafts (Zimmermann G. et al., 2013; Zimmermann et al., 2014).
Inhibition of PDEd could, however, also affect the distribution of
other cargo proteins, possibly leading to side effects and toxicity,
although PDEd knockout mice are viable (Zhang et al., 2007).
Furthermore, there is a discrepancy between the in vitro and
cellular nanomolar affinity of deltarasin and the observed micro-
molar concentrations that are needed for effective downregula-
tion of RAS signaling in tumor models. Further research should
unravel if this phenomenon depends on the inhibitor type or on
biological pathways that are not fully understood. These exam-
ples of targeting the localization and distribution mechanisms
to block RAS signaling, however, seem very promising strategies
and may also be extended to other putative prenyl-binding pro-
teins, such as calmodulin, PRA1, and galectins, for the develop-
ment of anticancer therapies.ACKNOWLEDGMENTS
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